These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 7954533)

  • 1. Haemodynamic impact of diuretic therapy in chronic heart failure.
    Silke B
    Cardiology; 1994; 84 Suppl 2():115-23. PubMed ID: 7954533
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Central hemodynamic effects of diuretic therapy in chronic heart failure.
    Silke B
    Cardiovasc Drugs Ther; 1993 Jan; 7 Suppl 1():45-53. PubMed ID: 8435376
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Value of aldosterone receptor blockade in diuretic therapy of patients with chronic heart failure].
    Christ M; Ludwig N; Maisch B
    Herz; 2002 Mar; 27(2):135-49. PubMed ID: 12025459
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Vasodilatation with captopril and prazosin in chronic heart failure: double blind study at rest and on exercise.
    Bayliss J; Canepa-Anson R; Norell MS; Poole-Wilson P; Sutton G
    Br Heart J; 1986 Mar; 55(3):265-73. PubMed ID: 3513808
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Urocortin 2 inhibits furosemide-induced activation of renin and enhances renal function and diuretic responsiveness in experimental heart failure.
    Rademaker MT; Charles CJ; Nicholls MG; Richards AM
    Circ Heart Fail; 2009 Nov; 2(6):532-40. PubMed ID: 19919977
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Haemodynamic and hormone responses to acute and chronic frusemide therapy in congestive heart failure.
    Ikram H; Chan W; Espiner EA; Nicholls MG
    Clin Sci (Lond); 1980 Dec; 59(6):443-9. PubMed ID: 7002435
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Diuretic therapy in congestive heart failure.
    Taylor SH
    Cardiol Rev; 2000; 8(2):104-14. PubMed ID: 11174882
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Classic treatment of chronic heart insufficiency. What if new?].
    Aumont MC; Agnola D; Juliard JM; Karrillon G
    Arch Mal Coeur Vaiss; 1995 Apr; 88(4 Suppl):599-602. PubMed ID: 7487308
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Progress in management for heart failure: diuretics].
    Aoyagi T; Hirata Y
    Nihon Rinsho; 1993 May; 51(5):1281-6. PubMed ID: 8331795
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Brain natriuretic peptide enhances renal actions of furosemide and suppresses furosemide-induced aldosterone activation in experimental heart failure.
    Cataliotti A; Boerrigter G; Costello-Boerrigter LC; Schirger JA; Tsuruda T; Heublein DM; Chen HH; Malatino LS; Burnett JC
    Circulation; 2004 Apr; 109(13):1680-5. PubMed ID: 15023890
    [TBL] [Abstract][Full Text] [Related]  

  • 11. In chronic heart failure with marked fluid retention, the i.v. high doses of loop diuretic are a predictor of aggravated renal dysfunction, especially in the set of heart failure with normal or only mildly impaired left ventricular systolic function.
    De Vecchis R; Ciccarelli A; Ariano C; Cioppa C; Giasi A; Pucciarelli A; Cantatrione S
    Minerva Cardioangiol; 2011 Dec; 59(6):543-54. PubMed ID: 21330961
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Balancing diuretic therapy in heart failure: loop diuretics, thiazides, and aldosterone antagonists.
    Paul S
    Congest Heart Fail; 2002; 8(6):307-12. PubMed ID: 12461320
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immediate effects of bumetanide on systemic haemodynamics and left ventricular volume in acute and chronic heart failure.
    Verma SP; Silke B; Reynolds G; Muller P; Frais MA; Taylor SH
    Br J Clin Pharmacol; 1987 Jul; 24(1):21-32. PubMed ID: 3304383
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Treatment of cardiac failure with enalapril].
    Bounhoure JP
    Presse Med; 1985 Dec; 14(44):2215-7. PubMed ID: 3003728
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Untreated heart failure: clinical and neuroendocrine effects of introducing diuretics.
    Bayliss J; Norell M; Canepa-Anson R; Sutton G; Poole-Wilson P
    Br Heart J; 1987 Jan; 57(1):17-22. PubMed ID: 3541995
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Conversion enzyme inhibitors in the treatment of chronic congestive cardiac failure. Physiopathologic bases of their use].
    Garabedian VG
    Presse Med; 1985 Dec; 14(44):2264-7. PubMed ID: 3003732
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Neurohumoral activation, regulation of sodium excretion and vasodilator treatment in heart insufficiency].
    Pimenta J; Pereira M; Castro A; Dias P; Azevedo A; Bettencourt P; Ferreira A
    Rev Port Cardiol; 2002 Feb; 21(2):157-62. PubMed ID: 11963285
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Diuretic therapy and resistance in congestive heart failure.
    Ellison DH
    Cardiology; 2001; 96(3-4):132-43. PubMed ID: 11805380
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Refocus on diuretics in the treatment of heart failure.
    Taylor SH
    Eur Heart J; 1995 Jul; 16 Suppl F():7-15. PubMed ID: 8521885
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The effects of treatment with octreotide, diuretics, or both on portal hemodynamics in nonazotemic cirrhotic patients with ascites.
    Kalambokis G; Economou M; Kosta P; Papadimitriou K; Tsianos EV
    J Clin Gastroenterol; 2006 Apr; 40(4):342-6. PubMed ID: 16633107
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.